|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-9-8
|
|
pubmed:abstractText |
Azathioprine is a useful agent in the management of inflammatory bowel disease. Its use is limited by its side-effect profile. Marrow toxicity occurs in approximately 3.2% of patients and is known to be associated with diminished thiopurine methyltransferase enzyme activity resulting from genetic polymorphisms.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0269-2813
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
593-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15352906-Adult,
pubmed-meshheading:15352906-Azathioprine,
pubmed-meshheading:15352906-Cost Savings,
pubmed-meshheading:15352906-Cost of Illness,
pubmed-meshheading:15352906-Cost-Benefit Analysis,
pubmed-meshheading:15352906-Genetic Testing,
pubmed-meshheading:15352906-Genotype,
pubmed-meshheading:15352906-Heterozygote,
pubmed-meshheading:15352906-Homozygote,
pubmed-meshheading:15352906-Humans,
pubmed-meshheading:15352906-Immunosuppressive Agents,
pubmed-meshheading:15352906-Inflammatory Bowel Diseases,
pubmed-meshheading:15352906-Methyltransferases,
pubmed-meshheading:15352906-Middle Aged,
pubmed-meshheading:15352906-Polymorphism, Genetic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
|
|
pubmed:affiliation |
Gastroenterology Unit, Gartnavel General Hospital, Glasgow, Scotland. jackwwinter@btopenworld.com
|
|
pubmed:publicationType |
Journal Article,
Validation Studies
|
